Who can use Yervoyg(Ipilimumab)?

Ipilimumab is an immune checkpoint inhibitor developed by Bristol Myers Squibb, primarily used for treating various advanced cancers, including melanoma, non-small cell lung cancer, renal cell carcinoma, etc. 

Who can use Yervoyg(Ipilimumab)?

It targets cytotoxic T lymphocyte antigen-4 (CTLA-4), blocks the binding of CTLA-4 to its ligands, thereby enhancing T-cell activity and promoting the immune system's attack on tumor cells.

On March 25, 2011, ipilimumab was approved for marketing by the U.S. 

Food and Drug Administration (FDA), becoming the world's first CTLA-4 inhibitor. Since then, the drug has been successively approved in multiple countries and regions, bringing new treatment options for patients with advanced cancers. In 2021, ipilimumab was formally approved by the National Medical Products Administration of China.